Status: Recruiting
DEPECA-1 - A Phase II Study to Evaluate a First-line Systemic Therapy With Enfortumab Vedotin Plus Avelumab for Advanced and Metastatic Penile Carcinoma
The DEPECA-1 trial is the first systematic Phase II trial to evaluate response and survival to a combination of antibody-drug conjugate enfortumab vedotin plus the PD-L1 inhibitor avelumab in patients with locally advanced and metastatic penile squamous cell carcinoma (PeCa) in the 1st line setting.
Participants needed: 25
Trial details
Phase: Phase 2Age: 18+Biological sex: MaleType: InterventionalSponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestUpdated: Jun 22, 2026Locations: 8
Eligibility criteria
Patient has ability to understand and the willingness to sign a written informed... [+20]
Previous systemic therapy for metastatic or locally advanced PeCa in the palliat... [+24]